Autologous bone marrow transplantation in the treatment of children and adolescents with advanced malignant tumors

Baumgartner, Christoph; Bleher, E. A.; Re, G. Brun del; Bucher, U; Deubelbeiss, Kurt; Greiner, Richard; Hirt, Andreas; Imbach, Paul; Lüthy, A; Odavic, R; Wägner, Hans

doi:10.1002/mpo.2950120209

Cited by 31 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless this is an encouraging number of complete responses in such a group and has hitherto not been obtainable by any conventional chemotherapy regimen (Cabanillas et aJ, 1982). This experience is similar to that reported by others (Baumgartner et al, 1983;Hartmann et a/, 1982). The previous treatment regimens were similar in the different institutions and the high dose regimens contained similar agents.…”

Section: Discussionsupporting

confidence: 92%

Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non‐Hodgkin's lymphoma

et al. 1985

View full text Add to dashboard Cite

50 cases of advanced, intermediate (18) and high grade (32) non-Hodgkin's lymphoma (NHL) including 16 with Burkitt lymphoma have been treated with very high dose chemotherapy and autologous bone marrow transplantation (ABMT). These cases represent a retrospective analysis of the combined experience of a recently established collaborative group. 31 patients were treated with a protocol used in Lyon, 12 with that used in Marseille and seven with that used in London. Although the details of drug administration differed, each protocol was based on high dose alkylating agent (cyclophosphamide or melphalan), BCNU and cytosine arabinoside. 16 patients had drug resistant progressive NHL. Of these 11 responded to high dose treatment (nine CR, two PR). The duration of CR in this group was short (median 104d) and only one patient was in CR at 1 year. 19 patients had relapsed on previous therapy but were still responding to conventional rescue therapy. Following high dose therapy 47% of these patients are in continuous CR with a median time of observation of 300 d (73-962 d). Seven patients were partial responders to conventional induction therapy. Of these, six had a CR with high dose treatment and are still in CR (range 39-1230 d, median 200 d). Eight patients received high dose therapy as intensification after a long delay to CR with conventional treatment. Of these, four are alive and in remission 124-763 d after treatment. The high dose protocols produced significant morbidity with 25 patients (50%) having major or minor treatment-related complications, and there were seven treatment related deaths (14%). However, these results indicate that durable responses can be obtained with high dose chemotherapy in patients who have been heavily treated and indicate a role for this type of treatment at an earlier stage in advanced non-Hodgkin's lymphoma.

show abstract

Section: Discussionsupporting

confidence: 92%

Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non‐Hodgkin's lymphoma

et al. 1985

View full text Add to dashboard Cite

show abstract

“…The results obtained with SFQG Super VAC protocol introduced in 1978 [3] for diffuse small noncleaved NHL with intraabdominal primary (6 survivors of 12 stage 111 and 2 of 4 stage IV patients [ 1 with bone marrow, 1 with CNS infiltration]) was degraded by the fact that 5 of 12 stage 111 patients died before autologous bone marrow reinfusion could be done. Taking all stage 111 and IV non-lymphoblastic NHL together, the survival rate of 56% [18,24] is similar or slightly better than that obtained with COMP (CCG-551) [21], NCI 77-04 [22], or POG 7905 [23].…”

Section: Discuss I0 Nmentioning

confidence: 85%

“…The study patients were treated according to a modified LSA,L,, the SPOG NHL protocol [6] (all stages and phenotypes), the SPOG Super VAC protocol with autologous bone marrow reinfusion [3] (B NHL stages I11 and IV with abdominal primary), the POG protocol 8314 [7] and 8719 for stages I and 11 (all phenotypes), POG protocols 8106 [8], 8616 [9], and 8617 for diffuse, non-lymphoblastic (B) NHL stages I11 and IV, the POG 8691 and 8704 for diffuse lymphoblastic (T) NHL stages 111 and IV, and POG 8615 for large cell NHL (Table 11). All protocols were approved by SPOG's Institutional Review Board.…”

Section: Methodsmentioning

confidence: 99%

Childhood NHL in Switzerland: Incidence and Survival of 120 Study and 42 Non‐Study Patients

Wagner

Dingeldein-Bettler

Berchthold

et al. 1995

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Based on the Swiss Pediatric Oncology Group (SPOG) cancer registry data during 1981-1991, a high average incidence of 8 new NHL per million children younger than 15 years per year was found. Of 162 children with NHL registered in 1976-1991, 120 were study patients, i.e., officially registered and treated according to SPOG or Pediatric Oncology Group (POG) protocols, while 42 were non-study patients, i.e., patients not officially enrolled on protocols. Overall, 91 of 120 (76%) study patients remained alive. Seventy-nine study patients were treated according to older SPOG protocols, and 53 (67%) of these survived, while 38 of 41 (93%) study patients treated according to newer POG protocols remained alive (P = 0.0068). Only 22 (52%) of the 42 non-study patients survived (P = 0.0001). There was no improvement if the survival of non-study patients before and since 1986 was compared. Population-based treatment results in Switzerland were similar to those in the United Kingdom. They provided an important base for the development of future treatment strategies.

show abstract

“…26 The first two years after diagnosis are generally regarded as the maximum at risk period, 27 although recurrence may occur later.28 The longterm prognosis for patients with resistant disease or early recurrence is generally very poor. Responses, including CRs, may be achieved with high-dose chemotherapy regimens, including some with autologous bone marrow rescue, 29 , 30 but their duration is usually short.…”

mentioning

confidence: 99%

High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy.

Pinkerton¹,

Pritchard²,

Spitz³

1986

JCO

View full text Add to dashboard Cite

A consecutive series of 13 children (five girls) with advanced malignant germ cell tumors (MGCTs) were treated with between four and seven (median, six) courses of cisplatin, bleomycin, and either vinblastine (BVP) or VP-16 (BEP). There were seven gonadal primaries (four testis, three ovary) and six at extragonadal sites (three sacrococcyx, two thoracic, one extradural). Total or subtotal removal of primary tumor was carried out in nine patients at diagnosis and two others after some chemotherapy. Clinical complete remission (CR) was achieved in nine of ten patients with measurable disease and serum markers returned to normal in all 13 patients. Eleven remain diseasefree 17 to 48 months (median, 28 months) after diagnosis. One patient (stage IV sacrococcygeal tumor) relapsed at the primary site 3 months after complet-MALIGNANT germ cell tumors (MGCTs) are the most common form of gonadal cancer in those under 15 years of age. Extragonadal primary sites include the mediastinum, sacrococ- 0732-183X/86/0402-0004$3.00/0 ing treatment, but is disease-free after further surgery, radiotherapy, and chemotherapy. Serial glomerular filtration rates were performed during treatment. Audiometry and pulmonary function tests were carried out where possible. Toxicity led to alteration of drug scheduling in two cases, but there were no permanent clinical renal, auditory, or pulmonary sequelae. These encouraging results confirm that MGCTs in children are as responsive as those in adults to cisplatin-containing chemotherapy and indicate that they may be as curable. The regimens are relatively well-tolerated and, with close monitoring, clinically significant toxicity should be avoidable.

show abstract

Autologous bone marrow transplantation in the treatment of children and adolescents with advanced malignant tumors

Cited by 31 publications

References 24 publications

Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non‐Hodgkin's lymphoma

Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non‐Hodgkin's lymphoma

Childhood NHL in Switzerland: Incidence and Survival of 120 Study and 42 Non‐Study Patients

High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy.

Contact Info

Product

Resources

About